These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 23442999)

  • 21. Measles: United States, January--May 20, 2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 May; 60(20):666-8. PubMed ID: 21617634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Measles in a Patient with Presumed Immunity - Los Angeles County, 2015.
    Kamali A; Bagchi CP; Mendoza E; Wilson D; Schwartz B; Mascola L
    MMWR Morb Mortal Wkly Rep; 2015 Oct; 64(39):1123. PubMed ID: 26447803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Measles and MMR immunization.
    Chorghade S
    Indian Pediatr; 2002 Jan; 39(1):108-11. PubMed ID: 11805369
    [No Abstract]   [Full Text] [Related]  

  • 24. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States.
    Zhou F; Reef S; Massoudi M; Papania MJ; Yusuf HR; Bardenheier B; Zimmerman L; McCauley MM
    J Infect Dis; 2004 May; 189 Suppl 1():S131-45. PubMed ID: 15106102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Measles in Mexico, 1941-2001: interruption of endemic transmission and lessons learned.
    Santos JI; Nakamura MA; Godoy MV; Kuri P; Lucas CA; Conyer RT
    J Infect Dis; 2004 May; 189 Suppl 1():S243-50. PubMed ID: 15106118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccine failures and vaccine effectiveness in children during measles outbreaks in New South Wales, March-May 2006.
    Sheppeard V; Forssman B; Ferson MJ; Moreira C; Campbell-Lloyd S; Dwyer DE; McAnulty JM
    Commun Dis Intell Q Rep; 2009 Mar; 33(1):21-6. PubMed ID: 19618764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
    Redd SC; King GE; Heath JL; Forghani B; Bellini WJ; Markowitz LE
    J Infect Dis; 2004 May; 189 Suppl 1():S116-22. PubMed ID: 15106100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.
    Peltola H; Heinonen OP; Valle M; Paunio M; Virtanen M; Karanko V; Cantell K
    N Engl J Med; 1994 Nov; 331(21):1397-402. PubMed ID: 7969278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine.
    LeBaron CW; Bi D; Sullivan BJ; Beck C; Gargiullo P
    Pediatrics; 2006 Oct; 118(4):1422-30. PubMed ID: 17015532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential impacts of schedule changes, waning immunity and vaccine uptake on measles elimination in Australia.
    Wood JG; Gidding HF; Heywood A; Macartney K; McIntyre PB; Macintyre CR
    Vaccine; 2009 Jan; 27(2):313-8. PubMed ID: 18977272
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Could the MMR vaccine replace the measles vaccine at one year of age in Egypt?
    Abbassy AA; Barakat SS; Abd El Fattah MM; Said ZN; El Metwally HA
    East Mediterr Health J; 2009; 15(1):85-93. PubMed ID: 19469430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Shortage of varicella and measles, mumps and rubella vaccines and interim recommendations from the Advisory Committee on Immunization Practices.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2002 Mar; 51(9):190-1. PubMed ID: 11905460
    [No Abstract]   [Full Text] [Related]  

  • 33. Humoral and cellular immune response after measles vaccination in Taiwan.
    Huang CL; Yang YH; Wang LC; Lin YT; Tsai YY; Chiang BL
    J Microbiol Immunol Infect; 2005 Jun; 38(3):169-75. PubMed ID: 15986066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Supplementary immunization activities to achieve measles elimination: experience of the European Region.
    Khetsuriani N; Deshevoi S; Goel A; Spika J; Martin R; Emiroglu N
    J Infect Dis; 2011 Jul; 204 Suppl 1():S343-52. PubMed ID: 21666183
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Measles immunization in Saudi Arabia: the need for change.
    Khalil MK; Al-Mazrou YY; Al-Jeffri M; Al-Ghamdy YS
    East Mediterr Health J; 2001; 7(4-5):829-34. PubMed ID: 15332786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Certain problems with limits of immunity against measles, mumps and rubella].
    Magdzik W
    Przegl Epidemiol; 1993; 47(1-2):47-53. PubMed ID: 8351387
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Measles-mumps-rubella revaccination; 18 months vs. 4-6 years of age: potential impacts of schedule changes.
    Saffar MJ; Fathpour GR; Parsaei MR; Ajami A; Khalilian AR; Shojaei J; Saffar H
    J Trop Pediatr; 2011 Oct; 57(5):347-51. PubMed ID: 21078605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MMR, measles, and the South Wales Evening Post.
    McCartney M
    BMJ; 2013 Apr; 346():f2598. PubMed ID: 23610382
    [No Abstract]   [Full Text] [Related]  

  • 39. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy.
    Laws HJ; Calaminus G; Göbel U
    Cancer; 2005 Apr; 103(8):1759; author reply 1760. PubMed ID: 15717299
    [No Abstract]   [Full Text] [Related]  

  • 40. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy.
    Fioredda F; Giacchino M; Castagnola E
    Cancer; 2005 Apr; 103(8):1758-9; author reply 1760. PubMed ID: 15717298
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.